TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04783376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Insulin, lispro and regular insulin
Description: * A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin.
Study: NCT05001776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation
Description: Laser ablation of the great saphenous vein close to sapheno-femoral junction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation
Description: Laser ablation of the great saphenous vein close to sapheno-femoral junction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: Fondaparinux sodium for 7 days or 45 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: Fondaparinux sodium for 7 days or 45 days
Study: NCT05720962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uninterrupted accompanying support
Description: When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm.
Study: NCT06313749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy Device
Description: During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
Study: NCT05728762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel LEDs
Description: LEDs with a continuous spectrum of 430-780 nm.
Study: NCT04358913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR scan with the Alberta linac-MR P3 system
Description: Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
Study: NCT04818489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the standard protocol only
Description: the local standard protocol for COVID19

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the standard protocol only
Description: the local standard protocol for COVID19
Study: NCT05406245

Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate drinking
Description: Administration of carbohydrate fluid
Study: NCT05287724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 1,500 mg twice daily for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 1,500 mg twice daily for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken twice daily for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken twice daily for seven days
Study: NCT05641324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion
Study: NCT05254587

Intervention type: DEVICE
Intervention: IOLMASTER 700 TK
Description: 4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.

Intervention type: DEVICE
Intervention: IOLMASTER 700 TK
Description: 4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
Study: NCT06074718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pricking therapy and wheat grain moxibustion
Description: pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pricking therapy and wheat grain moxibustion
Description: pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
Study: NCT04720313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC-201 (formerly HBI0101)
Description: NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
Study: NCT05641324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide with low-dose dexamethasone
Description: Lenalidomide and dexamethasone administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab administered by subcutaneous injection
Study: NCT05251519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
Study: NCT04954703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique of gluteus maximus and tensor fascia lata
Description: it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release of iliotibial band syndrome
Description: Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
Study: NCT04691557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
Study: NCT06310538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kou sha
Description: Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hongjin Xiaojie Capsules
Description: The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
Study: NCT05177224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound acquisitions to define liner position during movements
Description: Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate.
Study: NCT04748822

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
Study: NCT05479006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.
Study: NCT05027100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Tislelizumab Irinotecan
Description: Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
Study: NCT06011044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Block
Description: The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
Study: NCT05479006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.
Study: NCT06086470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qidni/D Hemodialysis System
Description: Qidni/D is a hemodialysis device for patients with end-stage renal disease.
Study: NCT05729646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Perioperative Toripalimab, 240 mg IV infusion
Study: NCT05479006

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.
Study: NCT05729646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Perioperative Toripalimab, 240 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study: NCT05251519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
Study: NCT06394700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written exposure therapy
Description: Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
Study: NCT04964557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT06394700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)
Description: WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal Contact Control (MCC)
Description: MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
Study: NCT05282186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises.
Study: NCT04467801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
Study: NCT06085118

Intervention type: OTHER
Intervention: Pepticate® Syneo®
Description: Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
Study: NCT05362838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
Study: NCT06248229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dyanavel XR
Description: Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.
Study: NCT05324878

Intervention type: OTHER
Intervention: Training
Description: Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
Study: NCT04803409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
Study: NCT05570838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Robotic-Assisted Therapy
Description: The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Robotic-Assisted Therapy
Description: The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
Study: NCT05962606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AON-D21
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study: NCT06368115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Educational materials on inappropriate prescribing and deprescribing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Educational materials on inappropriate prescribing and deprescribing.
Study: NCT05962606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.